• Experts critique press release of results from Moderna’s phase I vaccine trial, saying that more data are needed, triggering a 10% decrease in Moderna’s stock price. Source
• Health Canada authorizes a phase I/II trial of Can-Sino’s COVID-19 vaccine candidate. Source
